Floatz logo

Ipilimumab

Poorly Differentiated Thyroid Gland Carcinoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Poorly Differentiated Thyroid Gland Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
M.D. Anderson Cancer Center
Phase 2CCC
Lifileucel
M.D. Anderson Cancer Center
Phase 2CCC
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2CCC
Fludarabine
M.D. Anderson Cancer Center
Phase 2CCC
[177lu]lu-akir001
Karolinska University Hospital
Early Phase 1C
Gefetinib
National Cancer Institute (NCI)
N/ANR

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →